Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Hepion Pharmaceuticals, Inc. (HEPA)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
1.0100-0.0400 (-3.81%)
At close: 04:00PM EST
1.0300 +0.02 (+1.98%)
After hours: 04:32PM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close1.0500
Open1.0500
Bid1.0100 x 2200
Ask1.0300 x 1000
Day's Range1.0100 - 1.0595
52 Week Range1.0100 - 3.1800
Volume556,877
Avg. Volume767,011
Market Cap76.988M
Beta (5Y Monthly)1.39
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Hepion Pharmaceuticals Announces Death of Director, Thomas Adams

    EDISON, N.J., Jan. 12, 2022 (GLOBE NEWSWIRE) -- It is with profound sadness that Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA) announces the passing of Thomas Adams, Ph.D., a member of its Board of Directors. Dr. Adams died of natural causes on January 9, 2022. A seasoned biotechnology veteran, Dr. Adams was appointed to Hepion’s Board in September 2016. "We are deeply saddened by the loss of our dear friend and colleague,” said Hepion’s Chairman, Gary S. Jacob, Ph.D. “On behalf of the Company’s Bo

  • GlobeNewswire

    Hepion Pharmaceuticals Announces USAN Selection of “Rencofilstat” as Nonproprietary Name for CRV431

    EDISON, N.J., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis (“NASH”) and other liver diseases, today announced the United States Adopted Names (“USAN”) Council has adopted the nonproprietary name “rencofilstat” for the Company’s lead drug candidate, CRV431. The USAN Council (tri-sponsored by the

  • GlobeNewswire

    Hepion Pharmaceuticals Announces Participation in the H.C. Wainwright BioConnect Conference

    EDISON, N.J., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis (“NASH”) and other liver diseases, today announced that it will participate in the H.C. Wainwright BioConnect Conference, to be held virtually January 10-13, 2022. Hepion’s pre-recorded presentation will be available on demand during th

Advertisement
Advertisement